| Ms Lisa Marie Phifer, MD | |
|
415 W Columbia St Ste 100, Evansville, IN 47710-1656 | |
| (812) 450-6200 | |
| (812) 450-6202 |
| Full Name | Ms Lisa Marie Phifer |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 415 W Columbia St Ste 100, Evansville, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083880694 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 52514 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Deaconess Hospital Inc | 9032021431 | 308 |
News Archive
The National Science Foundation has awarded $8 million to a consortium led by the University of California, Irvine to develop a brain-computer interface that can restore walking ability and sensation in individuals with spinal cord injury.
The Boston Globe examines "'positive deviance,' an approach to behavioral and social change. Instead of imposing solutions from without, the method identifies outliers in a community who, despite having no special advantages, are doing exceptionally well. By respecting local ingenuity, proponents say, the approach galvanizes community members and is often more effective and sustainable than imported blueprints."
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
A recent study published on the preprint server medRxiv* in October 2020 suggests that arguments in favor of herd immunity are weakened by the fact that the steep increase in the number of COVID-19 deaths as a result of being exposed to the virus many times instead of once or a few times is not taken.
A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.
› Verified 7 days ago
| Entity Name | Deaconess Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427097443 PECOS PAC ID: 9032021431 Enrollment ID: O20040115000129 |
News Archive
The National Science Foundation has awarded $8 million to a consortium led by the University of California, Irvine to develop a brain-computer interface that can restore walking ability and sensation in individuals with spinal cord injury.
The Boston Globe examines "'positive deviance,' an approach to behavioral and social change. Instead of imposing solutions from without, the method identifies outliers in a community who, despite having no special advantages, are doing exceptionally well. By respecting local ingenuity, proponents say, the approach galvanizes community members and is often more effective and sustainable than imported blueprints."
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
A recent study published on the preprint server medRxiv* in October 2020 suggests that arguments in favor of herd immunity are weakened by the fact that the steep increase in the number of COVID-19 deaths as a result of being exposed to the virus many times instead of once or a few times is not taken.
A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.
› Verified 7 days ago
| Entity Name | Echo Community Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912906850 PECOS PAC ID: 4981515145 Enrollment ID: O20040721001319 |
News Archive
The National Science Foundation has awarded $8 million to a consortium led by the University of California, Irvine to develop a brain-computer interface that can restore walking ability and sensation in individuals with spinal cord injury.
The Boston Globe examines "'positive deviance,' an approach to behavioral and social change. Instead of imposing solutions from without, the method identifies outliers in a community who, despite having no special advantages, are doing exceptionally well. By respecting local ingenuity, proponents say, the approach galvanizes community members and is often more effective and sustainable than imported blueprints."
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
A recent study published on the preprint server medRxiv* in October 2020 suggests that arguments in favor of herd immunity are weakened by the fact that the steep increase in the number of COVID-19 deaths as a result of being exposed to the virus many times instead of once or a few times is not taken.
A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lisa Marie Phifer, MD Po Box 3407, Evansville, IN 47733-3407 Ph: (812) 450-6815 | Ms Lisa Marie Phifer, MD 415 W Columbia St Ste 100, Evansville, IN 47710-1656 Ph: (812) 450-6200 |
News Archive
The National Science Foundation has awarded $8 million to a consortium led by the University of California, Irvine to develop a brain-computer interface that can restore walking ability and sensation in individuals with spinal cord injury.
The Boston Globe examines "'positive deviance,' an approach to behavioral and social change. Instead of imposing solutions from without, the method identifies outliers in a community who, despite having no special advantages, are doing exceptionally well. By respecting local ingenuity, proponents say, the approach galvanizes community members and is often more effective and sustainable than imported blueprints."
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
A recent study published on the preprint server medRxiv* in October 2020 suggests that arguments in favor of herd immunity are weakened by the fact that the steep increase in the number of COVID-19 deaths as a result of being exposed to the virus many times instead of once or a few times is not taken.
A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.
› Verified 7 days ago
Dr. Eric Brackett, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 711 Saint Marys Dr, Evansville, IN 47714 Phone: 812-485-5858 | |
Mason M Plater, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 415 W Columbia St Ste 110, Evansville, IN 47710 Phone: 181-245-0606 | |
John T Gallagher, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 Saint Marys Dr # 300, Evansville, IN 47714 Phone: 812-485-5300 | |
Dr. Scott M Cordts, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 W Columbia St, Ste 110, Evansville, IN 47710 Phone: 812-450-3363 Fax: 812-450-3071 | |
Dr. Janet Marie Kelley, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 Bellemeade Ave Ste 200b, Evansville, IN 47714 Phone: 812-485-3737 | |
Natasha Elizabeth Mathew, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 415 W Columbia St Ste 110, Evansville, IN 47710 Phone: 812-450-3363 Fax: 812-450-3071 | |
Mike Sebastian, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 Bellemeade Ave, Suite 200-b, Evansville, IN 47714 Phone: 812-485-3737 Fax: 812-485-1704 |